Company

Novo Nordisk Opens Its Next Chapter With 'Lasting Health Starts Now' Rebrand and 'The Novo Way' Culture – Single 'Novo' Name Signals a Faster, Consumer‑Driven Era
Novo NordiskNYSE: NVO

Novo Nordisk Opens Its Next Chapter With ‘Lasting Health Starts Now’ Rebrand and ‘The Novo Way’ Culture – Single ‘Novo’ Name Signals a Faster, Consumer‑Driven Era

Novo Nordisk (NYSE: NVO) today unveiled a corporate rebrand centred on "Lasting Health Starts Now" and the single "Novo" name, together with an updated corporate culture, "The Novo Way", designed…

Sichuan Biokin's HER2 ADC T‑Bren Doses First Patient in Phase III Neoadjuvant Breast Cancer Trial – Head‑to‑Head Test Against Standard TCBHP Regimen

Sichuan Biokin’s HER2 ADC T‑Bren Doses First Patient in Phase III Neoadjuvant Breast Cancer Trial – Head‑to‑Head Test Against Standard TCBHP Regimen

Henlius' Denosumab Biosimilar HLX14 Gains NMPA BLA Acceptance – Fosun Pharma Subsidiary Targets Full Xgeva Label for China's Bone Health Market

Henlius’ Denosumab Biosimilar HLX14 Gains NMPA BLA Acceptance – Fosun Pharma Subsidiary Targets Full Xgeva Label for China’s Bone Health Market

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Takeda Secures NMPA Approval for Adzynma – China's First Recombinant ADAMTS13 Therapy for Congenital TTP
NYSE: TAKProduct approvals

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

ADC / XDCCancer

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

BiosimilarsHenlius Biotech

Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications

AbbVieNYSE: ABBV

AbbVie’s SKYRIZI (Risankizumab) Secures European Commission Approval for Pediatric Plaque Psoriasis – First IL-23 Inhibitor Authorized for Children as Young as Six

Show More